Illinois Clinical Trials Report — June 2026

For Illinois residents considering participation in clinical research, June 2026 presents a critical window of opportunity, particularly for trials nearing their enrollment deadlines. Across the state, 183 clinical trials are slated to close within the next 90 days, meaning time is running out to enroll. This includes 31 studies actively seeking healthy volunteers, offering a chance to contribute to medical science without a specific health condition.

Individuals living with certain health conditions should also act quickly to explore trials with impending deadlines. Research focusing on various neurological conditions, cancers, and chronic illnesses are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Duchenne muscular dystrophy (3 trials)
• Major depressive disorder (3 trials)
• Multiple sclerosis (3 trials)
• Breast cancer (3 trials)
• Stroke (3 trials)
• Knee osteoarthritis (3 trials)
• Hypertension (2 trials)
• Head and neck squamous cell carcinoma (2 trials)
• Ischemic stroke (2 trials)

New Research Initiatives Launch Across Illinois

This month, Illinois welcomes 48 new clinical trials, offering fresh avenues for participation. While this number is slightly lower than the 65 trials that opened in May 2026, it still represents a significant expansion of research opportunities across the state. These new studies include several notable Phase 3 drug trials from major pharmaceutical companies, offering participants access to cutting-edge treatments for widespread health challenges like obesity and type 2 diabetes, as well as crucial vaccine development.

• Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, is sponsoring NCT07654361, a Phase 3 study titled "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)." This substantial global study aims to enroll 3,600 participants to investigate the long-term efficacy, safety, and tolerability of aleniglipron for weight management.
• Pfizer is leading a vital Phase 3 vaccine trial, NCT07629440, "A Study to Learn About How a New Pneumococcal Vaccine Works in Infants." This global study seeks 3,230 participants to evaluate the safety and immune response of a new vaccine against pneumonia, meningitis, and otitis media in infants.
• For those with type 2 diabetes, AstraZeneca is sponsoring NCT07662109, a Phase 3 study investigating "The Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus." This trial plans for 2,000 participants to evaluate a new combination treatment for T2DM inadequately managed with lifestyle changes or existing treatments.
• Individuals experiencing migraines may be interested in NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine," a Phase 3 trial sponsored by Kallyope Inc., targeting 1,800 participants.
• A unique and large-scale study, NCT07656584, "Implementation of Communication Disability Collection and Accommodations in Primary Care Settings," is sponsored by NYU Langone Health. This multi-site study aims to enroll 126,870 participants to improve how primary care clinics document and accommodate patients' communication disabilities.
• For bladder cancer detection, Convergent Genomics, Inc. is sponsoring NCT07673016, "Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer." This observational study plans for 2,500 participants to collect urine and tumor biospecimens.
• Another diagnostic study, NCT07623902, "Evaluation of Gixam's Efficacy Predicting the Presence of Advanced and Non-advanced Colorectal Neoplasia in a FIT Negative Population," from Jubaan Ltd., seeks 1,436 participants to learn if a new device can identify pre-cancer or cancer in the colon and rectum.
• Finally, the Joint & Vascular Institute is conducting NCT07635784, the "Prospective HemorrhoIdaL EmboliSation (PILES) Registry," an observational study with 1,200 participants to collect real-world data on the effectiveness and safety of hemorrhoid artery embolization.

Diverse Conditions and Research Approaches

The 48 new trials opening this month in Illinois cover a diverse range of health conditions, with a notable focus on metabolic health and chronic pain. The most common conditions addressed by these new studies include:

• Obesity (3 trials)
• Chronic pain (2 trials)
• Overweight (2 trials)
• Enlarged prostate (BPH) (2 trials)
• Type 2 diabetes mellitus (2 trials)

In terms of intervention types, drug trials lead the way, accounting for 20 of the new studies. Other significant categories include "OTHER" interventions with 14 trials, and device trials with 7 new studies, alongside behavioral, procedure, biological, diagnostic test, and combination product research.

Illinois's Extensive Research Footprint

Illinois boasts a robust clinical research landscape, with 2,651 clinical trials currently recruiting across 154 cities and 1,561 research sites statewide. This month, the majority of new research initiatives are concentrated in the Chicago metropolitan area, which continues to be a central hub for clinical investigations. New trials opened in:

• Chicago (34 new trials)
• Evanston (4 new trials)
• Skokie (4 new trials)
• Naperville (2 new trials)
• Flossmoor (2 new trials)
• Grayslake (2 new trials)
• Mount Prospect (1 new trial)
• Niles (1 new trial)
• Northbrook (1 new trial)
• Oak Lawn (1 new trial)

This distribution ensures that while the Chicago area offers the most numerous opportunities, residents in various regions of Illinois also have access to cutting-edge research.

Participation Opportunities for All

For individuals without a specific medical condition, there are significant opportunities to contribute to medical science. Of the 48 new trials launched this month, 10 are actively seeking healthy volunteers. Statewide, a total of 318 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Clinical trials in Illinois are designed to be inclusive, with a broad range of eligibility criteria. Of the new trials, 7 include children as participants, and 41 include older adults, ensuring that research benefits diverse age groups. Gender-specific trials are also present, with 2 new studies open only to females and 4 open only to males.

Academic institutions continue to play a vital role in the state's research ecosystem, with Northwestern University sponsoring 8 of the new trials, followed by the University of Illinois at Chicago with 4, and the University of Chicago with 3. Industry sponsors are also driving significant research efforts, with 22 new trials sponsored by pharmaceutical companies such as AstraZeneca, Novo Nordisk A/S, and Eli Lilly and Company.

As we move through June, the focus will remain on the ongoing enrollment in these significant trials and the exploration of new treatments, diagnostics, and preventive measures for a broad spectrum of health challenges across Illinois.